Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Obesity drug study ends early, but Real-World data may still help

NCT ID NCT07081178

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see how well semaglutide works for weight loss in everyday medical practice, outside of a strict research setting. It involved 100 adults with obesity who were already planning to take the drug. The study was stopped early, so results are limited, but it may still provide useful information about real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Two groups of participants are planned to be included, one Group (A) with those initiating semaglutide adjunct with lifestyle modification, and the other Group (B) with those only with lifestyle modification.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Common inclusion criteria for Group A and Group B: 1. Male or female, age above or equal to 18 years at the time signing informed consent. 2. Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m\^2) with at least one of the following diagnosed obesity-related comorbidities: arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m\^2. 3. History of at least one self-reported unsuccessful attempt to lose weight. 4. Capable of completing informed consent. Additional inclusion criteria for Group A: 1. The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study. 2. Initiation of treatment is not modified in any case due to participant's participation in the study. Common exclusion criteria for Group A and Group B: 1. Previous participation in this study (participation is defined as having given informed consent in this study) 2. Treatment with an investigational drug within 30 days prior to enrolment into the study. 3. Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy. 4. Women with pregnancy or breast-feeding. 5. Women of childbearing potential and not using an adequate contraceptive method. 6. Men and women in their pregnancy attempts. 7. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 8. History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days. 9. History of type 1 or type 2 diabetes mellitus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

    Berlin, 13597, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.